With a focus on development of products that cater to unmet medical needs, we have worked relentlessly towards enriching lives of patients globally. Our business is structured into Discovery and Development of Novel Molecular Entities, Branded and Generic Formulations and Active Pharmaceutical Ingredients.

We are committed to address needs in the therapy areas of dermatology, oncology and respiratory. Today, we have a strong pipeline of novel molecules, both New Chemical Entities (NCEs) and New Biological Entities (NBEs), in pre-clinics and in various stages of clinical development.

Our branded formulations business focuses on developing innovative products in the areas of dermatology, respiratory and

cardio-metabolic therapy for patients across markets such as India, Brazil, Asia, Africa, Russia & CIS, for over 3 decades. In generics, we focus on developing high quality affordable products for the US and European markets.

Our Active Pharmaceutical Ingredients (API) division manufactures and supplies more than 190 high quality APIs to customers worldwide. We associate with leading global generic companies by supporting partnerships through advanced process chemistry skills and innovative intellectual property. Our API business spans over 80 countries including regulated markets of the US, Canada, Europe and Japan. We also are a market leader for many API products in semi-regulated markets with an established position in first-to-file offerings across regulated markets.